MSB 7.69% $1.19 mesoblast limited

Mesoblast - takeover target?, page-34

  1. 6,119 Posts.
    lightbulb Created with Sketch. 1053
    If Tasly was prudent they would of waited for the LVAD and CHF late stage results.

    They obviously wanted IN sooner, paid a premium and have their own agenda/plans for MSC's cellular medicine applications.

    Why did they want in sooner?
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.